Who are Tapinarof Cream 1%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): TAPINAROF, VTAMA (tapinarof) cream, 1%, ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tapinarof-cream-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tapinarof Cream 1% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tapinarof Cream 1% (Tapinarof Cream 1%) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Topical aryl hydrocarbon receptor agonist. Area: Dermatology.

phase 3 Topical aryl hydrocarbon receptor agonist Aryl hydrocarbon receptor Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Tapinarof Cream 1% (Tapinarof Cream 1%) — Teva Pharmaceuticals USA. Tapinarof is a topical aryl hydrocarbon receptor agonist that modulates the immune response and reduces inflammation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tapinarof Cream 1% TARGET	Tapinarof Cream 1%	Teva Pharmaceuticals USA	phase 3	Topical aryl hydrocarbon receptor agonist	Aryl hydrocarbon receptor
TAPINAROF	TAPINAROF		marketed	Aryl Hydrocarbon Receptor Agonist [EPC]	aryl hydrocarbon receptor (AhR)	2022-01-01
VTAMA (tapinarof) cream, 1%	VTAMA (tapinarof) cream, 1%	Organon and Co	marketed	Aryl hydrocarbon receptor (AhR) agonist	Aryl hydrocarbon receptor (AhR)
ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	ARQ-151 Cream 0.15% or ARQ-151 Cream 0.05%	Arcutis Biotherapeutics, Inc.	phase 3	Aryl hydrocarbon receptor (AhR) agonist	AhR (Aryl hydrocarbon receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Topical aryl hydrocarbon receptor agonist class)

Teva Pharmaceuticals USA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tapinarof Cream 1% — Competitive Intelligence Brief. https://druglandscape.com/ci/tapinarof-cream-1. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab